BioNotebook: Post-Thanksgiving blues for Exelixis, Pozen; Burrill notes tripling of M&A deals in 2014
This article was originally published in Scrip
Public companies often try to sneak their bad news into the evening hours following stock market closing time on the day before Thanksgiving – or on the eve of any major holiday, really – but Pozen and Exelixis waited until everyone came back to work from their turkey dinners and meals of endless leftovers to announce the loss of a major partner and a bad set of Phase III results.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.